BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

By S. Wilhelm, Christopher A. Carter, L. Tang, D. Wilkie, Angela Mcnabola, H. Rong, Charles Chen, Xiaomei Zhang, P. Vincent, M. McHugh and 16 more. Cancer Research, 2004

3,992 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/c957e06458f6fc3dc8add05609bb9dc0d10d5f1f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

In Oncology

Citations in the corpus

The genetic basis of kidney cancer: a metabolic disease (2010, background): “(29) Sunitinib also inhibits VEGF and PDGF receptors, and is most frequently used as a first-line agent in patients with advanced clear cell kidney cancer.”
Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium (2018, background): “Subsequently, an inhibitory activity was also demonstrated for VEGFR1/2 and PDFGR in several in vitro models (Wilhelm et al., 2004).”
Vascular endothelial growth factor (VEGF) signaling in tumor progression. (2007, background): “BAY 43-9006 inhibits everal protein kinases including VEGFR2, VEGFR3, Flt, Kit, PDGFR- , and Raf [274].”
Lessons from phase III clinical trials on anti-VEGF therapy for cancer (2006, background): “, Emeryville, CA) targets VEGFR2 and VEGFR3, PDGFR-β, Raf, c-Kit and FLT3 (fms-related tyrosine kinase 3), and efficiently inhibits both tumor-cell proliferation and angiogenesis in preclinical models”
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer (2007, background): “Compiled from studies cited in reviews that we have referenced in the text, from company websites and from www.clinicaltrials.gov; AML b Discontinued, c Also inhibitory activity for VEGFR-2, PDGFR-b, Flt-3, c-Kit and FGFR-1,”
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. (2006, background): “afenib was inhibition of tumor growth rather than tumor shrinkage.(3) These data suggested that, unlike”
Melanoma biology and new targeted therapy (2007, background): “The multi-kinase inhibitor sorafenib (BAY 43-9006) targets BRAF, CRAF and the VEGF and platelet-derived growth factor (PDGF) receptor tyrosine kinase”
Targeting the Mitogen-Activated Protein Kinase RAS-RAF Signaling Pathway in Cancer Therapy (2012, background): “The RAF family members, (A-Raf, B-Raf, and C-Raf or Raf-1), are highly conserved serine/threonine kinases of the MAPK [RAS--RAF--MEK--ERK] pathway (Figure 2).”
Focal Gains of Vascular Endothelial Growth Factor A and Molecular Classification of Hepatocellular Carcinoma (2008, background): “Intriguingly, KDR/ VEGFR-2 and FLT4/VEGFR-3 are among the putative targets of sorafenib (IC50 of 20–90 nmol/L), a multikinase inhibitor that has recently been shown to extend survival of patients with advanced hepatocellular carcinoma (46, 47).”